Pharmaceuticals

Global Pegfilgrastim Biosimilars Market Overview And Prospects

November 29, 2021 by The Business Research Company

Learn about the global pegfilgrastim biosimilars market through The Business Research Company, which provides information on pegfilgrastim biosimilars market size, pegfilgrastim biosimilars market drivers and restraints, pegfilgrastim biosimilars market players, the COVID-19 impact on the pegfilgrastim biosimilars market, and more.

Our annual holiday sale is here! Get your discounted market research reports today.

The global pegfilgrastim biosimilars market is expected to grow from $0.8 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.42 billion in 2025 at a CAGR of 13%.

Government initiatives for the development of biosimilars are expected to drive innovation in pegfilgrastim biosimilars manufacturing, thus driving the market during the forecast period.

Request A Sample For The Global Pegfilgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smph

The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.

Global pegfilgrastim biosimilars market segments include:

By Application: Chemotherapy Treatment, Transplantation, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years.

TBRC’s pegfilgrastim biosimilars market report covers:

Major Market Players: Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)

The Pegfilgrastim Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030 is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market overviews, analyzes and forecasts market size, share, pegfilgrastim biosimilars market players, pegfilgrastim biosimilars market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s pegfilgrastim biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here is a list of similar reports from The Business Research Company:

Interested to know more about The Business Research Company?

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our Blog: https://blog.tbrc.info/

Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model